tiprankstipranks
Advertisement
Advertisement
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
PremiumCompany AnnouncementsNuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
1M ago
Nuvation Bio falls -25.6%
Premium
The Fly
Nuvation Bio falls -25.6%
1M ago
Nuvation Bio falls -26.1%
Premium
The Fly
Nuvation Bio falls -26.1%
1M ago
Nuvation Bio Inc (NUVB) Q4 Earnings Cheat Sheet
PremiumPre-EarningsNuvation Bio Inc (NUVB) Q4 Earnings Cheat Sheet
1M ago
Nuvation Bio finalizes protocol amendment for study of safusidenib
Premium
The Fly
Nuvation Bio finalizes protocol amendment for study of safusidenib
2M ago
Nuvation Bio price target raised to $13 from $11 at Truist
Premium
The Fly
Nuvation Bio price target raised to $13 from $11 at Truist
2M ago
Nuvation Bio Expands Global Reach with Eisai Partnership
PremiumCompany AnnouncementsNuvation Bio Expands Global Reach with Eisai Partnership
3M ago
Nuvation Bio, Eisai enter exclusive taletrectinib license agreement
Premium
The Fly
Nuvation Bio, Eisai enter exclusive taletrectinib license agreement
3M ago
Nuvation Bio initiated with a Neutral at UBS
Premium
The Fly
Nuvation Bio initiated with a Neutral at UBS
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100